Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 18/20 | 0.51 |
| ▸ | MMP2 | P08253 | 13/20 | 0.51 |
| ▸ | MMP1 | P03956 | 10/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7215458 | 0.88 | MMP1 (0.43) | MMP13MMP2MMP1 | |
| SCHEMBL7216914 | 0.83 | MMP13 (0.53) | MMP13MMP2MMP1LMNA | |
| SCHEMBL7210443 | 0.82 | MMP13 (0.58) | MMP13MMP2MMP1 | |
| SCHEMBL7210298 | 0.80 | MMP13 (0.50) | MMP13MMP2MMP1MEN1NPC1 | |
| SCHEMBL7210869 | 0.80 | MMP13 (0.51) | MMP13MMP2MMP1 | |
| SCHEMBL7212030 | 0.80 | MMP13 (0.42) | MMP13MMP2MMP1HPGD | |
| SCHEMBL7210834 | 0.76 | MMP13 (0.61) | MMP13MMP2MMP1 | |
| SCHEMBL7216873 | 0.75 | MMP13 (0.51) | MMP13MMP2MMP1MEN1NPC1 | |
| SCHEMBL6764638 | 0.74 | MMP13 (0.67) | MMP13MMP2MMP1 | |
| SCHEMBL7216935 | 0.74 | MMP1 (0.47) | MMP13MMP2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030166687-A1 | ALPHA-HYDROXY,-AMINO AND -FLUORO DERIVATIVES OF BETA-SULPHONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS | PHARMACIA & UPJOHN COMPANY | 2003-09-04 | — | — | US | claimed |
| EP-1037868-B1 | $g(a)-HYDROXY, -AMINO, AND HALO DERIVATIVES OF $g(b)-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS | UPJOHN CO (US) | 2003-02-05 | — | — | EP | claimed |
| US-20030166687-A1 | ALPHA-HYDROXY,-AMINO AND -FLUORO DERIVATIVES OF BETA-SULPHONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS | PHARMACIA & UPJOHN COMPANY | 2003-09-04 | — | — | US | disclosed |
| EP-1037868-B1 | $g(a)-HYDROXY, -AMINO, AND HALO DERIVATIVES OF $g(b)-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS | UPJOHN CO (US) | 2003-02-05 | — | — | EP | disclosed |
| US-6437177-B1 | DISEASES INVOLVING CONNECTIVE TISSUE DEGRADATION; ARTHRITIS, OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CORNEAL, DERMAL, OR GASTRIC ULCERATION, AND ASTHMA; 2-HYDROXY-2-(PHENYLTHIO) METHYL-3-(4-BUTOXYBENZENESULFONYL)PROPIONIC ACID | PHARMACIA & UPJOHN COMPANY | 2002-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166687-A1 | ALPHA-HYDROXY,-AMINO AND -FLUORO DERIVATIVES OF BETA-SULPHONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS | MMP1, MMP8, HRH3 | MMP13 5/4885MMP2 8/4885MMP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.